24 Jun 2016
International Call for Applications for a Leader of 4-year research group within the Institut Pasteur in Côte d’Ivoire
Closing date for applications: September 30th, 2016
The Department of International Affairs of the Institut Pasteur is launching an international call for applications for future leader of 4-Year Groups (G4) within the Institut Pasteur in Côte d’Ivoire.
The candidate will be appointed head of a research group for 4 years and will receive start-up funding that includes his/her own salary and potentially that of engineers, technicians and doctoral students, as well as basic laboratory equipment and an operating budget. The candidate should subsequently obtain fresh funding to maintain his/her group on the longer term.
Chronic hepatitis, cirrhosis and primary liver cancer (mostly hepatocellular carcinomas), related to chronic Hepatitis B and C infections or other etiological factors, represent a major public health problem in African countries at large and in Côte d'Ivoire in particular. Biomarkers that might reliably indicate the stage and predict the evolution of the liver disease would be of major value for the implementation of the most appropriate and efficient measures for patients' management.
The Institut Pasteur in Côte d’Ivoire is a national institute whose missions include public health activities, teaching and research. It is part of the Institut Pasteur International Network that comprises 33 institutes worldwide.
Applications are completed exclusively online: http://g4.pasteur-international.org
Contact: Eliane Coëffier
For more information see the webpage: http://www.pasteur.fr/en/international/international-network-courses/4-year-group
24 Jun 2016
Félix Rey, Head of the Structural Virology Laboratory at the Institut Pasteur in Paris and his co-workers from the Institut Pasteur and the French National Centre for Scientific Research, in collaboration with Imperial College London and the University of Vienna, Austria, have identified antibodies that can efficiently neutralize both the dengue virus and the Zika virus. The description of the binding site for these antibodies on the viral envelope, identical for both viruses, could lead to the development of a universal vaccine that offers simultaneous protection against dengue and Zika virus disease. These results were published in the journal Nature on June 23, 2016.
3D structure of the Zika virus envelope protein (red, yellow and blue) in complex with the neutralizing antibody (in green and white). © Institut Pasteur
Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Lorière E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA
Nature (2016) doi:10.1038/nature18938
Read the full story on the Institut Pasteur website.
16 May 2016
From 18 to 20 May 2016, the nine institutes of the Asia-Pacific region will meet at the Institut Pasteur of Shanghai/Chinese Academy of Science. They will review their current institutional partnerships and initiate new ones. Discussions will help to develop specific research, public health as well as regional educational programs.
Different sessions will address the following topics: outbreaks and emergencies, antimicrobial resistance, cancers induced by viruses, industrial valorization, funding mechanisms and training & teaching strategies. The discussions ahead of the working groups meetings will be open to public.
The Institut Pasteur International Network includes 33 institutes around the world, located in 5 regional centers (i.e. Europe, Asia-Pacific, Americas, Africa, Maghreb-Iran). Each of these groups ensure a regional coverage on research, surveillance and control of infectious diseases, with close synergy between regions creating a common space to share technologies, methods, expertise resources and data throughout the 5 continents.
Please find the program of the meeting here.
The Institut Pasteur International Network Asia-Pacific Regional meeting will gather invited speakers, Institut Pasteur and Institut Pasteur International Network representatives and members of the nine institutes in the Asia-Pacific region:
- Institut Pasteur of Shanghai/Chinese Academy of Sciences
- Hong Kong University Pasteur Research Pole
- National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
- Institut Pasteur in Nha Trang, Vietnam
- Institut Pasteur in Ho Chi Minh City, Vietnam
- Institut Pasteur in Cambodia
- Institut Pasteur in New Caledonia
- Institut Pasteur in Laos
- Institut Pasteur in Korea
12 May 2016
While the Zika outbreak is currently one of the hot topic in the fields of virology and public health, another arbovirus stays close to international attention: Dengue virus. The world first dengue vaccine (Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur) has been registered in Mexico, the Philippines, Brazil and El Salvador. In April 2016, the WHO Advisory Group of Experts (SAGE) on immunization emitted its first recommendation after reviewing the vaccine: introduce it "only in geographic settings with high endemicity". WHO has announced that the organization will publish a more detailed report in July 2016 to specify its position and its recommendations regarding the vaccine.
Dr. Philippe Dussart, Institut Pasteur in Cambodia. © Healthwise
Dengvaxia and dengue vaccine development is just one of the subjects addressed by Dr. Philippe Dussart, Head of the Virology Unit at the Institut Pasteur in Cambodia in an interview called "The Dengue Peril" by the Cambodian magazine Healthwise Digest (Vol. 2 No.12 March 2016). Dr. Dussart comes back to the increase of dengue cases in Cambodia, the disease prevention, the time needed to develop vaccines, the absence of treatment drug.
Read the interview here.
10 May 2016
The Symposium on Transmission and Control of Respiratory Pathogens, jointly organized by the WHO Collaborating Centre for Infectious Disease Epidemiology and Control at the School of Public Health of the University of Hong Kong and the RGC Theme-based Research Scheme on Viral, Host and Environmental Determinants of Influenza Virus Transmission and Pathogenesis will take place on Tuesday 14 June 2016, from 14.00 to 18.00.
Venue: Cheung Kung Hai Conference Centre William MW Mong Block, 21 Sassoon Road, Pokfulam, Hong Kong
Professor Zhong Nan-Shan
Dr Werner E. Bischoff
Dr Samira Mubareka
Professor David Hui Shu-Cheong
Professor Malik Peiris
Professor Benjamin J. Cowling
Dr Joseph Wu Tsz-Kei
Dr Yen Hui-Ling
28 Apr 2016
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development
On March 7th, MRC Technology (Medical Research Council Technology transfer charity, UK) and Institut Pasteur of Shanghai, Chinese Academy of Sciences - IPS-CAS signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
Monoclonal antibody-based drugs have been established as one of the most successful therapeutic strategies for the treatment of infectious diseases, cancers and autoimmune diseases. “The promise of immune check-point antibodies and broadly neutralizing antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important”, said Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies.
Read more on IPS-CAS website: here